GlaxoSmithKline News and Research

RSS

Pertussis incidence: an interview with Leonard Friedland, M.D., V.P. and Director of Scientific Affairs and Public Health for GSK Vaccines

Distinguishing pertussis (also known as whooping cough) from other respiratory illnesses is challenging in particular among adults because the signs and symptoms of pertussis overlap with those of other respiratory diseases.

24 Oct 2013

Parental perceptions pose major barrier to acceptance of HPV vaccination

A Mayo Clinic physician and two other pediatric experts say that parental perceptions pose a major barrier to acceptance of human papillomavirus (HPV) vaccination — and that many of those perceptions are wrong.

22 Oct 2013

New article in Preventive Medicine journal explores suspicions about sexual promiscuity, vaccine safety

Suspicions about sexual promiscuity and vaccine safety are explored in an article in the November issue of the journal Preventive Medicine, which dedicates a section of that issue to research concerning the human papillomavirus.

18 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Eddingpharm Secures Immutep’s Immufact IMP321 For Growing Stable

Eddingpharm continued to aggressively build its product portfolio by inking another cancer agreement, this time with Immutep. In this latest agreement, Eddingpharm was granted exclusive rights to develop and market ImmuFact® IMP321 in mainland China, Hong Kong, Macau, and Taiwan.

7 Oct 2013

GSK Adds Another Program To Isis Antisense Collab

...

7 Oct 2013

GSK Sells Thrombosis Brands To Aspen For $1.13B

...

30 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

JPM, Bill & Melinda Gates Foundation announces capital raise for first-of-its-kind investment product

A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

24 Sep 2013

Google Eyes Wider Healthcare Footprint With Tech-Focused Calico

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Pertussis incidence among older adults may be under-recognized, study finds

The incidence of pertussis among U.S. adults 50 and older may be greatly under-reported and under-recognized, according to findings from a study conducted by GlaxoSmithKline researchers who analyzed approximately 48 million cases of cough-related illness in the U.S. between 2006 and 2010.

13 Sep 2013

2D Barcoding of U.S. vaccines: an interview with Dr. Leonard Friedland, VP, Director, Scientific Affairs and Public Health, GSK Vaccines North America

2D barcodes contain product identification, lot number, and expiration date. Linear barcodes only contain product identification information.

10 Sep 2013

Scientists provide proof of principle for drug-based treatment of acute pancreatitis

Scientists have for the first time provided proof of principle for a drug-based treatment of acute pancreatitis - a disease which is often alcohol-related and for which currently there is no treatment.

4 Sep 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

GlaxoSmithKline plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine.

19 Aug 2013

ASH announces 12 recipients of its second round of ASH Bridge Grants

As federal funding cuts continue to jeopardize the progress of biomedical research, the American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatments of blood disorders, today announced the 12 recipients of its second round of ASH Bridge Grants.

16 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013